The FDA-approved medication, Aducanumab, is under accelerated approval based on the reduction in amyloid plaques in patients treated with this medication in clinical trials. It is delivered as a monthly infusion.
The FDA approved lecanemab under accelerated approval based on reduction in amyloid plaques in patients treated with this medication in clinical trials. It is delivered as infusions every two weeks. The FDA decision on full approval of lecanemab is pending.
The Coronavirus (COVID-19) pandemic is challenging for everyone, especially for people with dementia and their caregivers.
It can be challenging living with dementia and caring for people with dementia. We have many resources to help support you.
There is so much information available on the internet, and it can be overwhelming to know where to get started. With this in mind, we have gathered some helpful links if you are new to this area.